Valuation : HighTide Therapeutics, Inc.

Market Cap 1.72B 2B 256M 220M 207M 189M 353M 24.45B 357M 2.47B 951M 12.4B 960M 939M 39.38B P/E 2024
-1.41x
P/E 2025 -5.19x
Enterprise Value 1.34B 1.57B 200M 172M 162M 148M 276M 19.09B 278M 1.93B 743M 9.68B 750M 733M 30.75B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
63.21%
Yield 2024 *
-
Yield 2025 -
1 day-4.36%
1 week+11.78%
Current month+10.38%
1 month+3.24%
3 months+28.57%
6 months+32.45%
Current year+18.98%
1 week 3.08
Extreme 3.08
3.85
1 month 2.96
Extreme 2.955
3.94
Current year 1.8
Extreme 1.8
4.72
1 year 1.8
Extreme 1.8
4.72
3 years 0.72
Extreme 0.72
13.18
5 years 0.72
Extreme 0.72
13.18
10 years 0.72
Extreme 0.72
13.18
Manager TitleAgeSince
Chief Executive Officer 56 01/01/2011
Director of Finance/CFO 57 01/12/2022
Chief Tech/Sci/R&D Officer - 02/02/2026
Director TitleAgeSince
Chairman 56 -
Director/Board Member 44 15/05/2023
Director/Board Member 68 30/11/2020
Date Insider Type Main position Quantity % Market Cap. Importance
30/4/26 Other

Director

1,800,000 0.3151%
1/4/26 Other

Chief Executive Officer

8,325,618 1.4572%
1/4/25 Other

Chief Executive Officer

3,960,550 0.7694%
Change 5-day change 1-year change 3-year change Capi.($)
-4.36%+11.78%-19.12% - 267M
-0.25%-0.96%+45.25%+102.76% 68.52B
-1.09%-6.20%+30.50%+74.05% 62.88B
-1.41%+0.45%-12.80%+380.17% 28.13B
-2.74%-3.53%+26.13%+13.50% 25.56B
-2.09%-6.40%-4.65%-18.36% 24.65B
-2.39%-5.19%+17.75%-19.64% 19.81B
-1.86%+1.15%+205.44%+353.89% 17.69B
-1.37%-3.77%-9.38%+528.34% 14.66B
-1.22%-2.45%+53.00%+162.30% 14.45B
Average -1.88%+0.49%+33.21%+175.22% 27.66B
Weighted average by Cap. -1.32%-1.39%+35.50%+138.39%

Financials

2024 2025
Net sales - -
Net income -382M -446M -56.89M -48.92M -46.16M -42.05M -78.61M -5.44B -79.32M -550M -212M -2.76B -214M -209M -8.76B -245M -286M -36.5M -31.39M -29.62M -26.98M -50.44M -3.49B -50.9M -353M -136M -1.77B -137M -134M -5.62B
Net Debt -413M -482M -61.51M -52.9M -49.91M -45.47M -84.99M -5.88B -85.76M -594M -229M -2.98B -231M -226M -9.47B -376M -439M -56.02M -48.18M -45.46M -41.41M -77.41M -5.36B -78.11M -541M -208M -2.72B -210M -206M -8.63B
Logo HighTide Therapeutics, Inc.
HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The Company has developed a product pipeline of multiple product candidates in-house, covering many indications in metabolic and digestive diseases among which, some are at clinical-stage. The Company’s core product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases. The Company conducts operations in the United States, Mainland China, Hong Kong and Australia.
Employees
55
Date Price Change Volume
10/09/26 HK$3.510 -4.36% 477,000
09/09/26 HK$3.670 +0.69% 1,395,500
08/09/26 HK$3.645 +15.35% 1,352,500
07/09/26 HK$3.160 +2.60% 487,000
04/09/26 HK$3.080 0.00% 337,500

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 2511 Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!